Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and animal mechanism-based research
PubMed 18604295 · doi:10.1155/2008/594868
What was done
The authors reviewed experimental and preclinical literature investigating erectile tissue-preserving and neuroregenerative treatment strategies for erectile dysfunction following nerve-sparing radical prostatectomy. Interventions evaluated across experimental models included intracavernous nitric oxide donors and vasoactive substances, oral PDE5 inhibitors, hyperbaric oxygen therapy, neuroimmunophilin ligands, neurotrophins, growth factors, and stem cell therapy.
What was found
No quantitative data, effect sizes, or statistical values are reported in the abstract. Qualitatively, erectile tissue preservation approaches (intracavernous NO donors/vasoactive substances, oral PDE5 inhibitors, hyperbaric oxygen) were reported to improve erectile function through antifibrotic effects and smooth muscle preservation. Neuroregenerative strategies (neuroimmunophilin ligands, neurotrophins, growth factors, stem cells) improved erectile function through the preservation of nitric oxide synthase-containing nerve fibers.
Why it matters
This review outlines the mechanistic rationale—specifically smooth muscle preservation, antifibrotic activity, and neuroprotection—supporting penile rehabilitation therapies after cavernous nerve injury. It synthesizes experimental targets that help inform clinical rehabilitation approaches.
Limits
The review synthesizes animal and laboratory models, which cannot establish clinical efficacy in humans. The abstract does not report the number of studies evaluated, search methodology, inclusion criteria, or numerical outcome metrics.
Cited by
- supports A lack of regular erections leads to reduced blood flow and progressive shrinkage of penile or clitoral tissue over time.